STAT+: Setting aside the thorniest issues around CRISPR babies, scientists say embryo-editing research should proceed
LONDON — The Francis Crick Institute is a glimmering chameleon of a building, spanning four…
Category: STAT+
STAT+: Veterans Health Administration will cover the newest Alzheimer’s drug
In an unexpected move, the Veterans Health Administration announced Monday that it will widely cover…
STAT+: Illumina has been ignoring its investors, but it can’t ignore Carl Icahn
Illumina, the DNA sequencing giant whose stock has fallen 40% in two years, already had…
STAT+: 102 hours of chaos: How SVB’s collapse rattled the biotech industry
Paul Rennert was surprisingly energized after deplaning a transatlantic flight in Boston Thursday evening. He…
STAT+: Pharmalittle: Biogen exec who quarterbacked Aduhelm leaves; Pfizer to buy Seagen for $43 billion
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: French pharma Sanofi buys maker of diabetes treatment for $2.9 billion
Sanofi said Monday that it is acquiring Provention Bio, makers of a diabetes treatment, for…
STAT+: Pfizer buys Seagen, maker of targeted cancer drugs, for $43 billion
Pfizer said Monday it is acquiring Seagen, a maker of targeted cancer drugs, for $43…
STAT+: Buyer’s remorse: How a Medicare Advantage business is strangling one of its first funders
When NaviHealth began building a business around using algorithms to scrutinize the care of older…
STAT+: Biogen’s Samantha Budd Haeberlein, an architect of Aduhelm, leaves company
Samantha Budd Haeberlein, the Biogen senior executive who supervised the development and controversial approval of…
STAT+: FDA approves first treatment for Rett syndrome, a genetic neurological disease
The Food and Drug Administration on Friday approved the first treatment for Rett syndrome, a…
STAT+: SVB, biotech’s bank of choice, just failed. It could have ripple effects
Silicon Valley Bank, which does business with roughly half of the nation’s tech and biotech…
STAT+: Pharmalittle: New York officials press pharmacy chains over abortion pill; Sanders pushes bill for $20 insulin cap
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Several years later, AstraZeneca says its drug extends life for some early-stage lung cancers
Ever since the Food and Drug Administration approved osimertinib for some early-stage lung cancer patients…
.jpg)
STAT+: Biden makes big demands for cancer research and new ARPA-H agency
President Biden is banking on longtime bipartisan interest in eliminating cancer deaths to secure some…
STAT+: Biden makes drug pricing a central part of his deficit reduction plans
WASHINGTON – President Biden made lowering drug prices a key part of his budget with…
STAT+: Insulin for $20 a vial? Sanders pushes bill for price caps on the diabetes treatment
Now that Eli Lilly is cutting prices on some of its insulin products, U.S. Sen….
STAT+: Mice with two fathers and base-edited baby monkeys highlight potential — and limitations — of hereditable gene editing
LONDON — Scientists at this year’s genome editing summit spent Tuesday showing the world just…
STAT+: Pharmalittle: Pharmacies are battlegrounds in the abortion debate; Lilly Alzheimer’s drug failed to prevent memory loss in study
Rise and shine, folks, another busy day is on the way. Already, there was a…
STAT+: ‘Emotional hunger’ vs. ‘hungry gut’: The attempt to subtype obesity and tailor treatments
This is part of a series about new obesity drugs that are transforming patients’ lives,…
STAT+: Pharmalittle: FDA head wants to get rid of advisory panel votes; premature-birth drug is finally withdrawn
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it…
STAT+: Controversial drug for premature birth is withdrawn by manufacturer after battle with FDA
After months of anticipation, the manufacturer of a controversial drug for premature births has agreed…
STAT+: Pharmalittle: Biden proposes expanding Medicare drug-price negotiation; Weight Watchers moves into obesity drug market
Top of the morning to you, and a fine one it is. Shiny and clear…
STAT+: Turkish court hands Novartis and Roche a rare win over their efforts to promote an eye treatment
A Turkish court overturned a decision by the national antitrust regulator that two years ago…
STAT+: Pharmalittle: ALS Association and its chapters battle over money and priorities; eye drops recalled over links to drug-resistant infections
And so, another working week will soon draw to a close. Not a moment too…
STAT+: They were the 10% left out of life-changing treatments. Now these cystic fibrosis patients may finally get help
Vertex Pharmaceuticals revolutionized the treatment of cystic fibrosis. It also has unfinished business. The Boston…
STAT+: Leading ALS advocacy group roiled by infighting over money and priorities
A blistering battle has broken out between the ALS Association and more than a dozen…
.jpg)
STAT+: Teva quits brand lobby PhRMA, in line to lead generic lobby AAM
WASHINGTON — Teva Pharmaceuticals has quit the Pharmaceutical Research and Manufacturers of America, STAT has…
STAT+: From industry ‘greed’ to workforce shortages, Sanders and Cassidy lay out health committee agenda
The Senate finally made long-expected committee assignments official on Thursday, kickstarting a new session for…
STAT+: Pharmalittle: GSK CEO warns U.K. pharma industry is at a ‘tipping point’; Gavi tussles with vaccine makers over refunds
Top of the morning to you. And a fine one it is. Sunny skies and…
STAT+: Biden administration floats major 2024 pay cut for Medicare Advantage plans
Medicare Advantage insurers could face an average 2.3% cut to baseline payments in 2024, the…
STAT+: FTC Commissioner criticizes $1.5 million GoodRx fine for health data leaks
On Wednesday, the Federal Trade Commission made history by enforcing, for the first time, its…
STAT+: New antidepressant study provides hints to Verily’s future
A small Phase 2 trial of a new antidepressant may hold clues to the direction…
STAT+: Pharmalittle: Pfizer projects lower revenue from Covid-19 products; Medicare eyes policy for paying less for accelerated-approval drugs
Top of the morning to you. The middle of the week is upon us and,…
STAT+: KKR veteran sets records with $3.9 billion health care fund
The former head of health care investing at private equity giant KKR has set records…
STAT+: 6 things to know about Apellis’ eye drug ahead of FDA decision
The Food and Drug Administration is nearing a decision on the first treatment for geographic…
STAT+: Pharmalittle: Amgen pricing for Humira biosimilar may not help patients; pharma wins court battle over drug discount program
Hello, everyone, and how are you this morning? We are just fine, thank you, although…
STAT+: Alphabet’s laid-off health tech employees on where their work heads next
Big Tech has gone through a rough stretch of layoffs — between Meta, Amazon, Alphabet,…
STAT+: FDA may not always require post-approval trials to be enrolled before accelerated approvals
WASHINGTON — A Food and Drug Administration official on Monday gave more clues for how…
STAT+: U.K. lawmakers urge Pfizer not to raise the price of its Covid-19 vaccine
Several U.K. lawmakers have asked Pfizer not to raise the price of its Covid-19 vaccine,…
STAT+: Pharma wins a key round in a court battle with hospitals over a drug discount program
In a victory for the pharmaceutical industry, a federal appeals court ruled drug companies have…
STAT+: FDA names former Oracle executive as new digital health leader
The Food and Drug Administration has installed Troy Tazbaz, most recently a senior vice president…
STAT+: Pharmalittle: Pfizer is scolded by U.K. industry group over CEO’s remarks on vaccination; Amgen to lay off 300 U.S. employees
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: ‘A classic case’: A legal expert on why lawsuits challenging abortion pill restrictions may succeed
A pair of lawsuits was filed last week challenging restrictions on access to abortion pills…
STAT+: ‘Everybody has blood on their hands’: A decade-long battle over Medicare Advantage audits is coming to a head
The federal government and health insurance companies have been clashing for more than a decade…
STAT+: No more ‘playing God’: How the longevity field is trying to recast its work as serious science
SAN FRANCISCO — “Why is it in popular culture, if you want to live forever, you…
STAT+: Inside the fall of star MIT scientist David Sabatini
The 7 a.m. Acela out of South Station in Boston trembled along the rails toward…
STAT+: After bullying allegations, Eric Lander will return to run a lab at the Broad Institute
After nearly a year of public silence and private speculation over Eric Lander’s next act,…
STAT+: Pfizer is scolded by a U.K. trade group for remarks its CEO made about vaccination
After weeks of deliberation, Pfizer was scolded by a U.K. pharmaceutical industry trade group after…
STAT+: Legend says its CAR-T outperformed conventional therapy for multiple myeloma
Legend Biotech said Friday that its CAR-T therapy Carvykti kept multiple myeloma patients’ cancer in…
STAT+: Pharmalittle: Some Republicans push to probe Pfizer over Covid-19 ‘mutations’; Warren urges FTC to probe pharma mergers
And so, another working week will soon draw to a close. Not a moment too…